Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands					12 Months Ended
	Nov. 16, 2023	Mar. 09, 2023	Mar. 10, 2022	Nov. 09, 2020	Dec. 31, 2023	Dec. 31, 2022	Jul. 31, 2023
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Reduction in workforce							86.00%
Proceeds from Sale of Equity Method Investments			$ 130,000
Net loss					$ 112,961	$ 5,005
Loss from operations					101,429	133,281
Accumulated deficit					$ 542,098	$ 429,137
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs		$ 250,000
Oxford Biomedica plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from Sale of Equity Method Investments			50,000
Upfront Payment Received			$ 130,000
ATM
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares					0
Proceeds through future financings					$ 75,000
ATM | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings		$ 75,000
ATM | Oxford Biomedica plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction			80.00%
ATM | Homology
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction			20.00%
Private Placement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares				5,000,000
Shares issued price per share				$ 12
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs				$ 60,000
Merger Agreement | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings	$ 80,000
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs	195,000
Concurrent Financing
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs	42,000
Concurrent Financing | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings	$ 42,000